KYORIN Pharmaceutical Co.,Ltd. (JP:4569) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
KYORIN Pharmaceutical Co., Ltd. has signed a licensing agreement with Bayer AG to exclusively manufacture, develop, and commercialize a novel treatment for obstructive sleep apnea, BAY2925976. This strategic move aims to address the significant health risks associated with untreated OSA by expanding treatment options, potentially enhancing patient care and quality of life. The agreement includes an upfront payment of EUR 15 million to Bayer, with additional milestone and royalty payments based on future developments.
For further insights into JP:4569 stock, check out TipRanks’ Stock Analysis page.